Lisata Therapeutics Company Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens.

The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc.

Country	United States
Founded	1980
Industry	Biological Products, Except Diagnostic Substances
Employees	26
CEO	David Mazzo

Contact Details

Address: 110 Allen Road Basking Ridge, New Jersey 07920 United States
Phone	908 842 0100
Website	lisata.com

Stock Details

Ticker Symbol	0HS8
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.	President, Chief Executive Officer and Director
James Nisco	Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer
Dr. Kristen K. Buck M.D.	Executive Vice President of Research & Development and Chief Medical Officer
Tariq Imam	Senior Vice President of Business Development and Operations and General Counsel
Gregory S. Berkin	Chief Information and Data Protection Officer
John D. Menditto	Vice President of Investor Relations and Corporate Communications
Dr. William K. Sietsema Ph.D.	Vice President of Global Regulatory Affairs